Format

Send to

Choose Destination
Int J Toxicol. 2010 Sep-Oct;29(5):467-78. doi: 10.1177/1091581810374372.

A novel formulation of ketorolac tromethamine for intranasal administration: preclinical safety evaluation.

Author information

1
SciLucent, LLC, Herndon, VA, USA.

Abstract

Ketorolac tromethamine is a potent analgesic and moderately effective anti-inflammatory drug approved for treatment of moderately severe acute pain as an intravenous/intramuscular injectable solution and an oral tablet. ROXRO PHARMA, Inc has developed an intranasal formulation, SPRIX, that delivers the drug with a similar pharmacokinetic profile to that obtained with intramuscular administration. Local tolerance and systemic toxicology studies were performed in rats and rabbits and showed that intranasal administration of SPRIX exhibits toxicity similar to that of other routes of administration and does not result in any adverse effects on the nasal passage and upper and lower respiratory system.

PMID:
20884857
DOI:
10.1177/1091581810374372
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center